axitinib

This page shows the latest axitinib news and features for those working in and with pharma, biotech and healthcare.

MSD’s Keytruda catches up in kidney cancer

Combination therapy approved in EU for all risk groups. MSD’s Keytruda in combination with Inlyta (axitinib) has won European Commission (EC) approval in the first-line treatment of the most ... The European approval of Keytruda with axitinib

Latest news

Keytruda scores in neoadjuvant triple negative breast cancer combo

Meanwhile, Keytruda is continuing to advance in other indications. In Europe, the Committee for Medicinal Products for Human Use (CHMP) has recommended Keytruda in combination with Inlyta (axitinib) as a
CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

Merck picked up another positive opinion for Keytruda, this time for use alongside Pfizer’s targeted cancer drug Inlyta (axitinib) for first-line treatment of renal cell carcinoma, and Bristol-Myers
Merck bulks up in cancer with $2.2bn Peloton buy

Keytruda is already making waves in RCC, having been approved for first-line RCC alongside Pfizer’s Inlyta (axitinib) in April.
Merck claims key FDA okay for Bavencio in kidney cancer

The FDA has just approved Pfizer-partnered Bavencio (avelumab) in combination with Pfizer’s Inlyta (axitinib) as a first-line therapy for patients with advanced renal cell carcinoma (RCC), the most
Keytruda combo outshines Opdivo in kidney cancer

s Inlyta (axitinib), shows it outperforming BMS’ pairing of Opdivo and Yervoy.

More from news
Approximately 5 fully matching, plus 29 partially matching documents found.

Latest Intelligence

Cancer immunotherapy: What's on the horizon?

They include Pfizer’s OX40 agonist PF-04518600, in early-stage testing in combination with the company’s Bavencio (avelumab) and targeted cancer drug Inlyta (axitinib) as well as chemotherapy,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Mirna hires former Pfizer director as CMO

Mirna will be banking on Dr Kim's extensive experience in oncology, which includes serving as global clinical lead for kidney cancer drugs Inlyta (axitinib) and Torisel (temsirolimus) during his time

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Oncology drugs under AMNOG

Pfizer’s Inlyta (axitinib) was approved in kidney cancer for patients pre-treated with either another targeted therapy, Sutent (sunitinib), or with older drugs called cytokines.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.